11/21/2024

Janusmed kön och genus

Janusmed kön och genus – misoprostol

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
B B
B B

Misoprostol

Misoprostol

Klass : B

Visa all info

Skriv ut

Kontakta oss

  1. Cytotec (misoprostol). Summary of Product Characteristics. Medical Products Agency (MPA); 2012.

  2. Physicians' Digital Reference. http://www.pdr.net. [cited 2017-07-12].

  3. CYTOTEC (misoprostol). Summary of Product Characteristics. http://www.medicines.org.uk/emc [cited 2017-07-12]

  4. Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess. 2007;11:iii-iv, 1-164.

  5. Hawkey CJ, Wilson I, Naesdal J, Långström G, Swannell AJ, Yeomans ND. Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. Gut. 2002;51:344-50.

  6. Hawkey CJ, Karrasch JA, Szczepañski L, Walker DG, Barkun A, Swannell AJ et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998;338:727-34.

  7. Misoprostol (misoprostol) DailyMed. DailyMed [www]. US National Library of Medicine. [updated 2016-02-12, cited 2017-07-12].

  8. Waiser J, Böhler T, Stoll J, Schumann B, Budde K, Neumayer HH. The immunosuppressive potential of misoprostol--efficacy and variability. Clin Immunol. 2003;109:288-94.

  9. Bergmann JF, Pichot L, de Pouvourville G, Chassany O, Caulin C, Segrestaa JM. [Prevention of gastroduodenal lesions induced by non-steroidal anti-inflammatory agents Economic analysis from a survey of 356 physicians]. Presse Med. 1992;21:979-82.

  10. Clinard F, Bardou M, Sgro C, Lefevre N, Raphael F, Paille F et al. Non-steroidal anti-inflammatory and cytoprotective drug co-prescription in general practice A general practitioner-based survey in France. Eur J Clin Pharmacol. 2001;57:737-43.

  11. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241-9.

  1. Cytotec (misoprostol). Summary of Product Characteristics. Medical Products Agency (MPA); 2012.
  2. Physicians' Digital Reference. http://www.pdr.net. [cited 2017-07-12].
  3. CYTOTEC (misoprostol). Summary of Product Characteristics. http://www.medicines.org.uk/emc [cited 2017-07-12]
  4. Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess. 2007;11:iii-iv, 1-164.
  5. Hawkey CJ, Wilson I, Naesdal J, Långström G, Swannell AJ, Yeomans ND. Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. Gut. 2002;51:344-50.
  6. Hawkey CJ, Karrasch JA, Szczepañski L, Walker DG, Barkun A, Swannell AJ et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998;338:727-34.
  7. Misoprostol (misoprostol) DailyMed. DailyMed [www]. US National Library of Medicine. [updated 2016-02-12, cited 2017-07-12].
  8. Waiser J, Böhler T, Stoll J, Schumann B, Budde K, Neumayer HH. The immunosuppressive potential of misoprostol--efficacy and variability. Clin Immunol. 2003;109:288-94.
  9. Bergmann JF, Pichot L, de Pouvourville G, Chassany O, Caulin C, Segrestaa JM. [Prevention of gastroduodenal lesions induced by non-steroidal anti-inflammatory agents Economic analysis from a survey of 356 physicians]. Presse Med. 1992;21:979-82.
  10. Clinard F, Bardou M, Sgro C, Lefevre N, Raphael F, Paille F et al. Non-steroidal anti-inflammatory and cytoprotective drug co-prescription in general practice A general practitioner-based survey in France. Eur J Clin Pharmacol. 2001;57:737-43.
  11. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241-9.